Formulary Monographs [MEFLOQUINE, 083008]
|
|
MEFLOQUINE
|
|
|
|
|
|
ANTIMALARIALS
|
|
|
Mefloquine is indicated for the prophylaxis and the treatment of mild to moderate malaria caused by Plasmodium vivax and susceptible strains of Plasmodium falciparum.
|
|
|
Anorexia, vomiting, nausea, diarrhoea, dizziness ,sleep disturbance, panic attacks, sudden on set of anxiety , restlessness, irritability, confusion, persistently abnormal heart beat, palpitations, bad dreams, depression sometimes profound, hallucinations and occasionally overt psychosis. Photosensitization has not been demonstrated. Take Mefloquine with food and a full glass of water. If medication is to be taken once a week, take on the same day each week.
|
|
|
Acute disease: 5 tablets (1250mg) should be given as a single oral dose or 750mg initially followed by 500mg given 12 hours later. Prophylaxis: 250mg per week prior to departure (commence 1-3weeks prior to travel), during period in endemic area and 4 weeks after return. Alternatively : 250mg for 3 days followed by 250mg weekly (in cases where a loading dose is required). (NB: 250mg M efloquine HCL = 228mg of the base).
|
|
|
When mefloquine is used for prevention or chemoprophylaxis of malaria in travelers, possible effects of mefloquine on other drugs these individuals are receiving (especially anticoagulants and antidiabetic agents) should be assessed prior to departure.
|
|
|
Manufacturer advises avoid unless the potential benefit outweighs the risk particularly in the first trimester.
|
|
|
Present in milk but risk to infant minimal.
|
|
|
|